The BPH group showed significantly increased prostatic index than that of the NC group (Figure 1C, p < 0.01), whereas the finasteride and ACE (AGEprost®)-treated groups showed a decrease in the prostate index relative to that of the BPH group. This evidence concerns the gene ACE and benign prostatic hyperplasia.